Evaluation of the Anti-Glycation Protective Effect of an Injectable Product Based on a Combination of Two Different Ranges of Molecular Weights of Hyaluronic Acid and Trehalose on Human Skin Explants
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073217 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Robert Chmielewski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Prime Clinic, Topiel 12, 00-342 Warsaw, Poland. Hauptthemen laut MEDLINE: Hyaluronic Acid, Trehalose, Skin, Glycation End Products, Advanced. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: URGO Sp. z o.o..
Abstract (Originalsprache)
Skin aging is significantly influenced by glycation processes, leading to the formation of Advanced Glycation End-products (AGEs) that compromise dermal structure and function. This study evaluated the protective effects of a novel injectable product based on a combination of two different ranges of Molecular Weights of Hyaluronic Acid (MWHA: LMWHA-Low MWHA, MMWHA-Mid MWHA, and HMWHA-High MWHA) and trehalose against glycation in human skin explants. Using human skin explants with methylglyoxal-induced glycation stress, we assessed the product’s impact on carboxymethyllysine (CML) formation and cell viability in the reticular dermis. The product was administered prophylactically one day before methylglyoxal exposure, and samples were analyzed after six days. Results demonstrated that the product significantly reduced CML formation by 45% (p < 0.01) compared to untreated controls under baseline conditions and maintained a 30% reduction (p < 0.05) in CML formation under methylglyoxal-induced stress. Importantly, the product preserved cell viability throughout the experimental period and maintained CML levels comparable to physiological baseline despite glycation stress. These findings suggest that the synergistic action of hyaluronic acid and trehalose provides effective protection against both baseline and induced glycation in human skin, indicating potential applications in preventing glycation-related skin aging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Prime Clinic, Topiel 12, 00-342 Warsaw, Poland.
- Positive Pro-Aging Foundation, Topiel 12, 00-342 Warsaw, Poland.
- URGO Aesthetics Department, URGO Sp. z o.o., Aleje Jerozolimskie 142 B, 02-305 Warsaw, Poland.
- Department of Basic Biomedical Science, Faculty of Pharmaceutical Science, Medical University of Silesia in Katowice, Jednosci 8B, 41-208 Sosnowiec, Poland.
- Department of Dermatology, Venereology, and Allergology, Faculty of Medicine, Medical University of Gdańsk, Smoluchowskiego 17, 80-214 Gdańsk, Poland.
ORCID-Profile: Robert Chmielewski, Agata Lebiedowska, Wioletta Barańska-Rybak
Förderung
- URGO Sp. z o.o.
Zitieren
APA
Chmielewski, R., Lebiedowska, A., & Barańska-Rybak, W. (2025). Evaluation of the Anti-Glycation Protective Effect of an Injectable Product Based on a Combination of Two Different Ranges of Molecular Weights of Hyaluronic Acid and Trehalose on Human Skin Explants. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073217
Vancouver
Chmielewski R, Lebiedowska A, Barańska-Rybak W. Evaluation of the Anti-Glycation Protective Effect of an Injectable Product Based on a Combination of Two Different Ranges of Molecular Weights of Hyaluronic Acid and Trehalose on Human Skin Explants. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073217
BibTeX
@article{Chmielewski2025,
author = {Chmielewski, Robert and Lebiedowska, Agata and Barańska-Rybak, Wioletta},
title = {Evaluation of the Anti-Glycation Protective Effect of an Injectable Product Based on a Combination of Two Different Ranges of Molecular Weights of Hyaluronic Acid and Trehalose on Human Skin Explants},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073217}
}
EUVIMED